'On standalone basis

Quarter ended June 2025 compared with Quarter ended June 2024.

Net sales (including other operating income) of Pfizer has increased 7.14% to Rs 603.05 crore.  Operating profit margin has jumped from 31.53% to 34.83%, leading to 18.33% rise in operating profit to Rs 210.02 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 9.50% to 14.66%.   Purchase of finished goods cost fell from 30.88% to 20.55%.   Employee cost increased from 15.04% to 15.84%.   Other expenses fell from 15.36% to 14.22%.   

Other income up 60.54% to Rs 67.17 crore.  PBIDT rose 26.38% to Rs 277.19 crore.  Provision for interest up 54.03% to Rs 3.25 crore.  

PBDT rose 26.11% to Rs 273.94 crore.  Provision for depreciation down 1.30% to Rs 14.41 crore.  

Profit before tax grew 28.09% to Rs 259.53 crore.&nbs...

• 

  (17-Jan-2026)

  Federal Bank

  Healthy all-round performance
• 

  (17-Jan-2026)

  Fedbank Financial Services

  AUM growth accelerates to 17%, spreads improve
• 

  (17-Jan-2026)

  Tech Mahindra

  NP up 14.1% YoY to Rs 1122 crore in Q3FY2026
• 

  (17-Jan-2026)

  Wipro

  Revenue up 5.5% yoy to Rs 23555.8 crore in Q3FY2026